Inhaled corticosteroids used by preschool-aged children at risk ofasthma will not prevent the disease from developing, according toNHLBI. The findings of a multicenter clinical trial from thePrevention of Early Asthma in Kids (PEAK) study, supported byNHLBI, answered the question as to whether treatment of airwayinflammation early enough could prevent the development of asthma.
Corticosteroids lack disease-modifying effect
Inhaled corticosteroids used by preschool-aged children at risk of asthma will not prevent the disease from developing, according to NHLBI. The findings of a multicenter clinical trial from the Prevention of Early Asthma in Kids (PEAK) study, supported by NHLBI, answered the question as to whether treatment of airway inflammation early enough could prevent the development of asthma. The study examined 285 children aged two to three years at high risk of asthma who were treated with fluticasone propionate (Flovent) or placebo for two years. After the second year, all children stopped their treatment and were observed for an additional 12 months for long-lasting effects. Results showed no differences between the two groups in the frequency or severity of asthma-related symptoms, leading researchers to believe treatment with the steroids does not alter the natural course of the disease.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.